These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 31909673)
21. Preliminary evidence of hippocampal damage in chronic users of ecstasy. den Hollander B; Schouw M; Groot P; Huisman H; Caan M; Barkhof F; Reneman L J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):83-5. PubMed ID: 21444322 [TBL] [Abstract][Full Text] [Related]
22. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417 [TBL] [Abstract][Full Text] [Related]
23. Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands. Brunt TM; Niesink RJ; van den Brink W Int J Drug Policy; 2012 Mar; 23(2):134-40. PubMed ID: 21741814 [TBL] [Abstract][Full Text] [Related]
24. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163 [TBL] [Abstract][Full Text] [Related]
25. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users. Parrott A Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401 [No Abstract] [Full Text] [Related]
26. Evidence for significant polydrug use among ecstasy-using college students. Wish ED; Fitzelle DB; O'Grady KE; Hsu MH; Arria AM J Am Coll Health; 2006; 55(2):99-104. PubMed ID: 17017306 [TBL] [Abstract][Full Text] [Related]
34. Is the use of ecstasy and hallucinogens increasing? Results from a community study. Schuster P; Lieb R; Lamertz C; Wittchen HU Eur Addict Res; 1998 Mar; 4(1-2):75-82. PubMed ID: 9740820 [TBL] [Abstract][Full Text] [Related]
35. What is a dose of ecstasy? Cole JC; Sumnall HR; Wagstaff GF J Psychopharmacol; 2002 Jun; 16(2):189-90. PubMed ID: 12095080 [No Abstract] [Full Text] [Related]
36. The epidemiology of ecstasy use and harms in Australia. Degenhardt L; Roxburgh A; Dunn M; Campbell G; Bruno R; Kinner SA; George J; Quinn B; White N; Topp L Neuropsychobiology; 2009; 60(3-4):176-87. PubMed ID: 19893334 [TBL] [Abstract][Full Text] [Related]
37. Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naïve controls. Morgan MJ; Impallomeni LC; Pirona A; Rogers RD Neuropsychopharmacology; 2006 Jul; 31(7):1562-73. PubMed ID: 16292322 [TBL] [Abstract][Full Text] [Related]
38. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910 [TBL] [Abstract][Full Text] [Related]
39. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998 [TBL] [Abstract][Full Text] [Related]
40. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Schifano F; Oyefeso A; Corkery J; Cobain K; Jambert-Gray R; Martinotti G; Ghodse AH Hum Psychopharmacol; 2003 Oct; 18(7):519-24. PubMed ID: 14533133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]